TY - JOUR T1 - Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2022-002693 VL - 8 IS - 2 SP - e002693 AU - José Luis Martín-Varillas AU - Lara Sanchez-Bilbao AU - Vanesa Calvo-Río AU - Alfredo Adán AU - Inés Hernanz AU - Adela Gallego-Flores AU - Emma Beltran-Catalan AU - Sonia Castro-Oreiro AU - Patricia Fanlo AU - Alvaro Garcia Martos AU - Ignacio Torre AU - Miguel Cordero-Coma AU - Juan Ramon De Dios AU - Ángel García-Aparicio AU - Marisa Hernández-Garfella AU - Amalia Sánchez-Andrade AU - Andrea García-Valle AU - Olga Maiz AU - Roberto Miguélez AU - Sergio Rodríguez-Montero AU - Ana Urruticoechea AU - Raúl Veroz AU - Arantxa Conesa AU - Cristina Fernández-Carballido AU - Vega Jovaní AU - Jose J Mondejar AU - Olga Martínez González AU - Patricia Moya Alvarado AU - Susana Romero-Yuste AU - Paula Rubio-Muñoz AU - Eva Peña-Sainz-Pardo AU - Marta Garijo-Bufort AU - Rosalía Demetrio-Pablo AU - José L Hernández AU - Ricardo Blanco Y1 - 2022/12/01 UR - http://rmdopen.bmj.com/content/8/2/e002693.abstract N2 - Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet’s disease (n=10), psoriatic arthritis (n=8), Crohn’s disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.No data are available. ER -